

# The Neuro4D Conference 2026

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**MONDAY  
MAY 04<sup>TH</sup>**

|                                                                                                                                                            |                                                                                                                               |                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|
| 8:00 – 8:30                                                                                                                                                |                                                                                                                               |                                                                    |
| Registration and Joint Breakfast in Foyer, attach Posters                                                                                                  |                                                                                                                               |                                                                    |
| 8:30 – 8:55                                                                                                                                                |                                                                                                                               |                                                                    |
| Opening of the Conference – <i>Andreas Köpke, bioExpert</i>                                                                                                |                                                                                                                               |                                                                    |
| 8:55                                                                                                                                                       |                                                                                                                               |                                                                    |
| Development of the Life ScienceHub Mainz – <i>Tim Roos, biomindz</i>                                                                                       |                                                                                                                               |                                                                    |
| 9:00 – 9:30                                                                                                                                                |                                                                                                                               |                                                                    |
| Cellular Senescence and Aging in Neurodegenerative Diseases:<br>Opportunities for Drug Discovery?<br><i>Chair: Roger Sher, Stony Brook University, USA</i> |                                                                                                                               |                                                                    |
| PANEL 09:30 – 10:30                                                                                                                                        |                                                                                                                               |                                                                    |
| Senescence in Neurodegeneration                                                                                                                            | HMGB1 mediates senescence and cognitive dysfunction in tauopathies                                                            | <b>Rakez Kayed</b><br>UTMB, USA                                    |
|                                                                                                                                                            | Aging, inflammation, and neurodegeneration:<br>Unraveling the senescent brain in Parkinson's disease                          | <b>Markus Riesland</b><br>Stony Brook University, USA              |
| Animal Models of PD                                                                                                                                        | <i>In vivo</i> models for Parkinson's disease translation:<br>Connecting mechanism, efficacy, and biomarkers                  | <b>Ayşe Ulusoy</b><br>DZNE Bonn, Germany                           |
| Panel Q&A of Session Speakers<br><i>Chair: Roger Sher, Stony Brook University, USA</i>                                                                     |                                                                                                                               |                                                                    |
| 10:30 – 11:30                                                                                                                                              |                                                                                                                               |                                                                    |
| Coffee Break, Exhibition & Poster viewing                                                                                                                  |                                                                                                                               |                                                                    |
| PANEL 11:30 – 12:30                                                                                                                                        |                                                                                                                               |                                                                    |
| New AD Mode of Action                                                                                                                                      | Identification of a novel Aβ(pGlu3-x) targeting pathway in Alzheimer's disease                                                | <b>Sarah Schrepel</b><br>University of Leipzig, Germany            |
| New AD Mode of Action                                                                                                                                      | Finding the right target for Aβ immunotherapy – PTM-targeting antibodies differentially mediate inflammation and phagocytosis | <b>Stefan Schilling</b><br>IZI Fraunhofer Inst., Germany           |
|                                                                                                                                                            | Lysosome targeting in Parkinson's disease: From pathophysiology to therapy                                                    | <b>Friederike Zunke</b><br>Friedrich-Alexander-University, Germany |
| Panel Q&A of Session Speakers<br><i>Chair: Roger Sher, Stony Brook University, USA</i>                                                                     |                                                                                                                               |                                                                    |
| 12:30                                                                                                                                                      |                                                                                                                               |                                                                    |
| Lunch                                                                                                                                                      |                                                                                                                               |                                                                    |

# The Neuro4D Conference 2026

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**MONDAY  
MAY 04<sup>TH</sup>**

|                                                                                                                                                                       |                                                                                                                          |                                                                                 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| 13:30                                                                                                                                                                 |                                                                                                                          |                                                                                 |
| TREM2 agonism – where do we stand and what is needed for therapy?<br><i>Chair: Christian Haass, DZNE, LMU, Germany</i>                                                |                                                                                                                          |                                                                                 |
| PANEL 14:00 – 15:00                                                                                                                                                   |                                                                                                                          |                                                                                 |
| Neuroinflammation                                                                                                                                                     | Brain-Shuttle mediated TREM2 PET for highly specific assessment of activated myeloid cells                               | Matthias Brendel<br>LMU, Germany                                                |
|                                                                                                                                                                       | TREM2 activation: Harnessing the brain's immune system to treat neurodegeneration                                        | Agnes Cheong<br>Sanofi, UK                                                      |
|                                                                                                                                                                       | Transport vehicle engineering improves activity of TREM2 antibodies                                                      | Lihong Zhan<br>Denali, USA                                                      |
| Panel Q&A of Session Speakers<br><i>Chair: Christian Haass, DZNE, LMU, Germany</i>                                                                                    |                                                                                                                          |                                                                                 |
| 15:00 – 16:00                                                                                                                                                         |                                                                                                                          |                                                                                 |
| Coffee Break, Exhibition & Poster Session<br>(Presenters will be at their posters.)<br>Time for One on One Meetings                                                   |                                                                                                                          |                                                                                 |
| PANEL 16:00 – 17:00                                                                                                                                                   |                                                                                                                          |                                                                                 |
| Neuroinflammation                                                                                                                                                     | Inhibition of prolyl endopeptidase to reduce neuroinflammation                                                           | Franziska Richter Assencio<br>Center for Systems Neuroscience Hannover, Germany |
| Service Company Presentation                                                                                                                                          | De-risking drug development in neurodegenerative and age-related diseases                                                | Stefan Ebner-Behnke<br>Scantox, Austria                                         |
| TDP-43 Aggregates and Disease                                                                                                                                         | Misfolded TDP-43 transmits intercellularly via large seeding particles, and is toxic intracellularly via small oligomers | Neil Cashman<br>UBC, Canada                                                     |
| Panel Q&A of Session Speakers<br><i>Chair: Christian Haass, DZNE, LMU, Germany</i>                                                                                    |                                                                                                                          |                                                                                 |
| 17:00                                                                                                                                                                 |                                                                                                                          |                                                                                 |
| Reception in the foyer with local wine and beer specialties                                                                                                           |                                                                                                                          |                                                                                 |
| 17:30                                                                                                                                                                 |                                                                                                                          |                                                                                 |
| From Data to Dialogue: Toasting to Better Science Conversations<br><i>Laura Lindenfeld, Alan Alda Center for Communicating Science, USA</i>                           |                                                                                                                          |                                                                                 |
| 18:30 – 22:00                                                                                                                                                         |                                                                                                                          |                                                                                 |
| Dinner<br>We will have a seated BBQ dinner, accompanied by fitting local wines!<br>Depending on the weather, we will be on the hotel terrace, or in an adjacent room. |                                                                                                                          |                                                                                 |
| END OF THE FIRST DAY                                                                                                                                                  |                                                                                                                          |                                                                                 |

# The Neuro4D Conference 2026

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**TUESDAY  
MAY 05<sup>TH</sup>**

| 8:00                                                                                                                                                                                             |                                                                                                            |                                             |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Joint Breakfast, Exhibition & Poster Viewing                                                                                                                                                     |                                                                                                            |                                             |
| PANEL 9:00 – 10:00                                                                                                                                                                               |                                                                                                            |                                             |
| New MoA                                                                                                                                                                                          | Amisulpride derivative as novel drug in tau-associated neurodegenerative diseases                          | Josephine Labus<br>MHH, Germany             |
| Clearing toxic protein aggregates                                                                                                                                                                | Detangling toxic aggregates                                                                                | Dieter Willbod<br>Priavoid, Germany         |
| Therapeutic Improvements                                                                                                                                                                         | Delivering $\alpha$ -synuclein antibodies into the brain via the BrainTransporter technology               | Fredrik Eriksson<br>Bioarctic, Sweden       |
| <b>Panel Q&amp;A of Session Speakers</b><br>Chair: Wiebke Jürgens-Wemheuer, Uni. Saarland, Germany                                                                                               |                                                                                                            |                                             |
| 10:00 – 11:00                                                                                                                                                                                    |                                                                                                            |                                             |
| Coffee Break, Exhibition & Poster Session<br>(Presenters will be at their posters.)<br>Time for One on One Meetings                                                                              |                                                                                                            |                                             |
| 11:00 – 11:30                                                                                                                                                                                    |                                                                                                            |                                             |
| <b>On the trail of protein aggregates: using RT-QuIC to detect <math>\alpha</math>-synuclein aggregates in salivary gland biopsies</b><br>Chair: Wiebke Jürgens-Wemheuer, Uni. Saarland, Germany |                                                                                                            |                                             |
| PANEL 11:30 – 12:30                                                                                                                                                                              |                                                                                                            |                                             |
| Blood diagnosis                                                                                                                                                                                  | Neuro-IP as method for improvement of Alzheimer's disease diagnostic by blood tests                        | Ingolf Lachmann<br>Roboscreen GmbH, Germany |
| Nasal sampling for diagnosis                                                                                                                                                                     | Beyond CSF and Blood: Nasal fluid as a window into brain biology                                           | Sabine Mertzig<br>Noselab, Germany          |
| Seed quantification                                                                                                                                                                              | From misfolding to medicine: SeNostic's Seed Cyclor enables diagnosis and drug discovery for proteopathies | Joachim Glaubitz<br>SeNostic, Germany       |
| <b>Panel Q&amp;A of Session Speakers</b><br>Chair: Wiebke Jürgens-Wemheuer, Uni. Saarland, Germany                                                                                               |                                                                                                            |                                             |
| 12:30                                                                                                                                                                                            |                                                                                                            |                                             |
| Lunch                                                                                                                                                                                            |                                                                                                            |                                             |

# The Neuro4D Conference 2026

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**TUESDAY  
MAY 05<sup>TH</sup>**

| 13:30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                            |                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|
| Disease modifying therapies in Alzheimer's disease based on individual neurobiological staging<br><i>Chair: Oliver Peters, Charité, Germany</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                            |                                                            |
| PANEL 14:00 – 15:00                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                            |                                                            |
| New Therapeutic Option                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | TRB-001, a novel $\alpha$ -synuclein-based vaccine for the treatment and prevention of Parkinson's disease | <b>Achim Schneeberger</b><br>Tridem Bioscience,<br>Austria |
| Therapeutic Improvements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | tbd                                                                                                        | <b>Jennifer Murphy</b><br>Biogen, USA                      |
| Marketing approval and reimbursement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | From EMA to G-BA: Implementing anti-amyloid therapy in Germany                                             | <b>Lutz Frölich</b><br>U. Heidelberg, Germany              |
| Panel Q&A of Session Speakers<br><i>Chair: Oliver Peters, Charité, Germany</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                            |                                                            |
| 15:00                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                            |                                                            |
| Coffee Break & Final Poster Session                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                            |                                                            |
| 15:30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                            |                                                            |
| <p>Panel Diskussion:</p> <ul style="list-style-type: none"><li>• Is the GBA decision justified and final - and what does that mean for future AD therapy developments? How can the current immunotherapy be improved in terms of efficacy and safety?</li><li>• How accurate are current and developing diagnostics for neurodegenerative diseases and what are the implications for patients and therapies?</li><li>• Should new therapies focus on neuroinflammation and improvement of synaptic health?</li></ul> <p>Panel Participants: <i>Oliver Peters, Lutz Frölich, Neil Cashman, Wiebke Wemheuer, Christian Haass</i><br/>Moderator: <i>Andreas Köpke, bioExpert</i></p> |                                                                                                            |                                                            |
| 16:15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                            |                                                            |
| Potser price, Summary and Wrap-up of the conference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                            |                                                            |
| 16:30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                            |                                                            |
| END OF THE CONFERENCE AND DEPARTURE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                            |                                                            |